The Journal of Clinical Investigation (Jan 2023)

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection

  • Satomi Ando,
  • Charles M. Perkins,
  • Yamato Sajiki,
  • Chase Chastain,
  • Rajesh M. Valanparambil,
  • Andreas Wieland,
  • William H. Hudson,
  • Masao Hashimoto,
  • Suresh S. Ramalingam,
  • Gordon J. Freeman,
  • Rafi Ahmed,
  • Koichi Araki

Journal volume & issue
Vol. 133, no. 2

Abstract

Read online

T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differentiated TIM3+ cells, a part of which possesses effector-like properties. PD-1–targeted therapies enhance T cell response by promoting differentiation of stem-like T cells toward TIM3+ cells, but the role of mTOR during T cell exhaustion remains elusive. Here, we showed that mTOR inhibition has distinct outcomes during the beginning of and after the establishment of chronic viral infection. Blocking mTOR during the T cell expansion phase enhanced the T cell response by causing accumulation of stem-like T cells, leading to improved efficacy of PD-1 immunotherapy; whereas, after exhaustion progressed, mTOR inhibition caused immunosuppression, characterized by decreased TIM3+ cells and increased viral load with minimal changes in stem-like T cells. Mechanistically, a cell-intrinsic mTOR signal was vital for differentiation of stem-like T cells into the TIM3+ state in the early and late phases of chronic infection as well as during PD-1 immunotherapy. Thus, PD-1 blockade worked after cessation of mTOR inhibition, but simultaneous treatment failed to induce functional TIM3+ cells, reducing efficacy of PD-1 immunotherapy. Our data demonstrate that mTOR regulates T cell exhaustion and have important implications for combination cancer therapies with PD-1 blockade.

Keywords